comprehensive -WSS

comprehensive

author：knowledge 2025-10-01 11:00:03 - browse：89

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： PBM reform efforts get punted in Congress

hotspot

focus

WSS

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

The aspartame in Diet Coke probably isn’t giving you cancer

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

6 phony surgeries that take placebo to the extreme

Judge agrees to delay next hearing in Trump classified documents case

White House announces new plan to address the growing threat of xylazine in overdose crisis

explore

comprehensive

knowledge

Guidelines to prevent youth baseball injuries need more muscle

The U.S. needs a new definition of substance use “recovery”

Novavax promises a turnaround & Lilly roils the obesity market

Alabama hospital puts IVF treatments on hold

At least 13 dead in Texas as scorching temps continue

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

DIEP, the 'gold standard' of breast reconstruction, is under threat

In utero gene editing: an explainer

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Wikipedia

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

He's a Nobel laureate. Critics say he was misleading on Covid

See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

A new nitrogen execution bill also undermines medical licensing

Antivenom research: Lessons from HIV applied in search for universal antidote

focus

hotspot

focus

leisure time